These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

259 related articles for article (PubMed ID: 25291977)

  • 1. Cost-effectiveness of rapid hepatitis C virus (HCV) testing and simultaneous rapid HCV and HIV testing in substance abuse treatment programs.
    Schackman BR; Leff JA; Barter DM; DiLorenzo MA; Feaster DJ; Metsch LR; Freedberg KA; Linas BP
    Addiction; 2015 Jan; 110(1):129-43. PubMed ID: 25291977
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The cost-effectiveness of rapid HIV testing in substance abuse treatment: results of a randomized trial.
    Schackman BR; Metsch LR; Colfax GN; Leff JA; Wong A; Scott CA; Feaster DJ; Gooden L; Matheson T; Haynes LF; Paltiel AD; Walensky RP
    Drug Alcohol Depend; 2013 Feb; 128(1-2):90-7. PubMed ID: 22971593
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-effectiveness of hepatitis C screening and treatment linkage intervention in US methadone maintenance treatment programs.
    Schackman BR; Gutkind S; Morgan JR; Leff JA; Behrends CN; Delucchi KL; McKnight C; Perlman DC; Masson CL; Linas BP
    Drug Alcohol Depend; 2018 Apr; 185():411-420. PubMed ID: 29477574
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-Effectiveness of One-Time Hepatitis C Screening Strategies Among Adolescents and Young Adults in Primary Care Settings.
    Assoumou SA; Tasillo A; Leff JA; Schackman BR; Drainoni ML; Horsburgh CR; Barry MA; Regis C; Kim AY; Marshall A; Saxena S; Smith PC; Linas BP
    Clin Infect Dis; 2018 Jan; 66(3):376-384. PubMed ID: 29020317
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Peginterferon alfa and ribavirin for chronic hepatitis C in patients eligible for shortened treatment, re-treatment or in HCV/HIV co-infection: a systematic review and economic evaluation.
    Hartwell D; Jones J; Baxter L; Shepherd J
    Health Technol Assess; 2011 Apr; 15(17):i-xii, 1-210. PubMed ID: 21473834
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Health outcomes and cost-effectiveness of diversion programs for low-level drug offenders: A model-based analysis.
    Bernard CL; Rao IJ; Robison KK; Brandeau ML
    PLoS Med; 2020 Oct; 17(10):e1003239. PubMed ID: 33048929
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-effectiveness of Early Treatment of Hepatitis C Virus Genotype 1 by Stage of Liver Fibrosis in a US Treatment-Naive Population.
    Chahal HS; Marseille EA; Tice JA; Pearson SD; Ollendorf DA; Fox RK; Kahn JG
    JAMA Intern Med; 2016 Jan; 176(1):65-73. PubMed ID: 26595724
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The cost-effectiveness of improved hepatitis C virus therapies in HIV/hepatitis C virus coinfected patients.
    Linas BP; Barter DM; Leff JA; DiLorenzo M; Schackman BR; Horsburgh CR; Assoumou SA; Salomon JA; Weinstein MC; Kim AY; Freedberg KA
    AIDS; 2014 Jan; 28(3):365-76. PubMed ID: 24670522
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-effectiveness of Hepatitis C Virus Treatment Models for People Who Inject Drugs in Opioid Agonist Treatment Programs.
    Gutkind S; Schackman BR; Morgan JR; Leff JA; Agyemang L; Murphy SM; Akiyama MJ; Norton BL; Litwin AH; Linas BP
    Clin Infect Dis; 2020 Mar; 70(7):1397-1405. PubMed ID: 31095683
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The cost-effectiveness of testing for hepatitis C in former injecting drug users.
    Castelnuovo E; Thompson-Coon J; Pitt M; Cramp M; Siebert U; Price A; Stein K
    Health Technol Assess; 2006 Sep; 10(32):iii-iv, ix-xii, 1-93. PubMed ID: 16948891
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-effectiveness of integrated treatment for hepatitis C virus (HCV) among people who inject drugs in Norway: An economic evaluation of the INTRO-HCV trial.
    Lim AG; Aas CF; Çağlar ES; Vold JH; Fadnes LT; Vickerman P; Johansson KA
    Addiction; 2023 Dec; 118(12):2424-2439. PubMed ID: 37515462
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-effectiveness of Universal and Targeted Hepatitis C Virus Screening in the United States.
    Tatar M; Keeshin SW; Mailliard M; Wilson FA
    JAMA Netw Open; 2020 Sep; 3(9):e2015756. PubMed ID: 32880650
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Elimination of hepatitis C virus in Germany: modelling the cost-effectiveness of HCV screening strategies.
    Krauth C; Rossol S; Ortsäter G; Kautz A; Krüger K; Herder B; Stahmeyer JT
    BMC Infect Dis; 2019 Dec; 19(1):1019. PubMed ID: 31791253
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-effectiveness of integrating buprenorphine-naloxone treatment for opioid use disorder into clinical care for persons with HIV/hepatitis C co-infection who inject opioids.
    Barocas JA; Morgan JR; Fiellin DA; Schackman BR; Eftekhari Yazdi G; Stein MD; Freedberg KA; Linas BP
    Int J Drug Policy; 2019 Oct; 72():160-168. PubMed ID: 31085063
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-Effectiveness Analysis of Early Treatment of Chronic HCV with Sofosbuvir/Velpatasvir in Italy.
    Ruggeri M; Romano F; Basile M; Coretti S; Rolli FR; Drago C; Cicchetti A
    Appl Health Econ Health Policy; 2018 Oct; 16(5):711-722. PubMed ID: 30039348
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-effectiveness of mass screening for Hepatitis C virus among all inmates in an Irish prison.
    Ward Z; Mafirakureva N; Stone J; Keevans M; Betts-Symonds G; Crowley D; McHugh T; Avramovic G; Lambert JS; Vickerman P
    Int J Drug Policy; 2021 Oct; 96():103394. PubMed ID: 34412938
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Boceprevir for previously untreated patients with chronic hepatitis C Genotype 1 infection: a US-based cost-effectiveness modeling study.
    Ferrante SA; Chhatwal J; Brass CA; El Khoury AC; Poordad F; Bronowicki JP; Elbasha EH
    BMC Infect Dis; 2013 Apr; 13():190. PubMed ID: 23621902
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-effectiveness of the HepCATT intervention in specialist drug clinics to improve case-finding and engagement with HCV treatment for people who inject drugs in England.
    Ward Z; Reynolds R; Campbell L; Martin NK; Harrison G; Irving W; Hickman M; Vickerman P
    Addiction; 2020 Aug; 115(8):1509-1521. PubMed ID: 31984606
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-effectiveness of scaling-up HCV prevention and treatment in the United States for people who inject drugs.
    Barbosa C; Fraser H; Hoerger TJ; Leib A; Havens JR; Young A; Kral A; Page K; Evans J; Zibbell J; Hariri S; Vellozzi C; Nerlander L; Ward JW; Vickerman P
    Addiction; 2019 Dec; 114(12):2267-2278. PubMed ID: 31307116
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost effectiveness of screening strategies for early identification of HIV and HCV infection in injection drug users.
    Cipriano LE; Zaric GS; Holodniy M; Bendavid E; Owens DK; Brandeau ML
    PLoS One; 2012; 7(9):e45176. PubMed ID: 23028828
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.